英国《皮肤科医师协会银屑病生物制剂治疗指南》（2020版）解读

doi:10.16150/j.1671-2870.2021.01.005

摘要/Abstract

中图分类号:

R758.63

史玉玲. 英国《皮肤科医师协会银屑病生物制剂治疗指南》（2020版）解读[J]. 诊断学理论与实践, 2021, 20(01): 37-42.

图/表 1

参考文献 24

[1]	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2018完整版)[J]. 中华皮肤科杂志, 2019, 52(10):667-710.
[2]	丁晓岚, 王婷琳, 沈佚葳, 等. 中国六省市银屑病流行病学调查[J]. 中国皮肤性病学杂志, 2010, 24(7):598-601.
[3]	王晓晖. 西南4省市银屑病流行病学调查研究[J]. 哈尔滨医药, 2017, 37(5):426-427.
[4]	Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics[J]. J Am Acad Dermatol, 2019, 80(4):1029-1072. doi: S0190-9622(18)33001-9 pmid: 30772098
[5]	Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update[J]. Br J Dermatol, 2020, 183(4):628-637. doi: 10.1111/bjd.19039 URL
[6]	Samarasekera E, Sawyer L, Parnham J, et al. Assessment and management of psoriasis: summary of NICE guidance[J]. BMJ, 2012, 345:e6712. doi: 10.1136/bmj.e6712 URL
[7]	NICE pathways. 2020 Musculoskeletal conditions overview[R/OL].(2020-02-25) http://pathways.nice.org.uk/pathways/musculoskeletalconditions#content=view_node%3Anodes-psoriatic-arthritis&path=view%3A/pathways/musculoskeletal_conditions/arthritis.xml In, Vol. [Accessed 26th February 2020].
[8]	Samarasekera EJ, Smith CH, National Institute of Health and Care Excellence, et al. Psoriasis: guidance on assessment and referral[J]. Clin Med (Lond), 2014, 14(2):178-182.
[9]	Eworuke E, Panucci G, Goulding M, et al. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants[J]. Pharmacoepidemiol Drug Saf, 2019, 28(3):296-304. doi: 10.1002/pds.4695 pmid: 30430682
[10]	Ferreira C, Azevedo A, Nogueira M, et al. Management of psoriasis in pregnancy - a review of the evidence to date[J]. Drugs Context, 2020, 9:2019-11-6.
[11]	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物治疗专家共识(2019)[J]. 中华皮肤科杂志, 2019, 52(12):863-871.
[12]	Motaparthi K, Stanisic V, Van Voorhees AS, et al. From the Medical Board of the National Psoriasis Foundation: recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoria-sis[J]. J Am Acad Dermatol, 2014, 70(1):178-186. doi: 10.1016/j.jaad.2013.08.049 pmid: 24220724
[13]	Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biologi-cal therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)[J]. Clin Microbiol Infect, 2018, 24(Suppl 2):S10-S20. doi: 10.1016/j.cmi.2017.12.025 URL
[14]	Mikulska M, Lanini S, Gudiol C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens[I]: CD19, CD20 and CD52)[J]. Clin Microbiol Infect, 2018, 24(Suppl 2):S71-S82. doi: 10.1016/j.cmi.2018.02.003 URL
[15]	Ekong N, Curtis H, Ong E, et al. Monitoring of older HIV-1-positive adults by HIV clinics in the United Kingdom: a national quality improvement initiative[J]. HIV Med, 2020, 21(7):409-417. doi: 10.1111/hiv.12842 pmid: 32125760
[16]	Murdaca G, Negrini S, Pellecchio M, et al. Update upon the infection risk in patients receiving TNF alpha inhibitors[J]. Expert Opin Drug Saf, 2019, 18(3):219-229. doi: 10.1080/14740338.2019.1577817 URL
[17]	Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries[J]. Eur Respir J, 2015, 46(6):1563-1576. doi: 10.1183/13993003.01245-2015 URL
[18]	Doherty SD, van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents[J]. J Am Acad Dermatol, 2008, 59(2):209-217. doi: 10.1016/j.jaad.2008.03.023 pmid: 18485527
[19]	Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: anti-tumor necrosis factor-α and beyond[J]. Clin Chest Med, 2019, 40(4):721-739. doi: S0272-5231(19)30056-5 pmid: 31731980
[20]	Canouï E, Launay O. History and principles of vaccination[J]. Rev Mal Respir, 2019, 36(1):74-81. doi: S0761-8425(18)30971-9 pmid: 30579659
[21]	Dobson R, Giovannoni G. Multiple sclerosis - a review[J]. Eur J Neurol, 2019, 26(1):27-40. doi: 10.1111/ene.13819 pmid: 30300457
[22]	Generali E, Carrara G, Kallikourdis M, et al. Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept[J]. Rheumatol Int, 2019, 39(2):239-243. doi: 10.1007/s00296-018-4196-9 pmid: 30413926
[23]	Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis[J]. Cochrane Database Syst Rev, 2020, 1(1):CD011535.
[24]	Oranges CM, Schaefer DJ. Implications of rheumatic di-sease and biological response-modifying agents in plastic surgery[J]. Plast Reconstr Surg, 2016, 138(1):158e. doi: 10.1097/PRS.0000000000002312 URL

生物制剂	靶抗原	维持治疗阶段常规剂量	疗效欠佳时剂量调整
依那西普（etanercept）	TNF-α	50 mg每周1次,皮下注射	50 mg每周2次,皮下注射
英夫利西单抗（infliximab）	TNF-α	5 mg/kg每8周1次,静脉滴注	5 mg/kg每6周1次,静脉滴注
阿达木单抗(adalimumab）	TNF-α	40 mg每2周1次,皮下注射	40 mg每周1次,皮下注射
赛妥珠单抗(certolizumab)	TNF-α	200 mg每2周1次,皮下注射	400 mg每2周1次,皮下注射
乌司奴单抗(ustekinumab）	IL-12/23p40	体重≤100 kg,45 mg每12周1次,皮下注射; 体重>100 kg,90 mg每12周1次,皮下注射	体重≤100 kg,90 mg每8周或12周1次, 皮下注射;体重>100 kg,90 mg每8周1次, 皮下注射
替拉珠单抗(tildrakizumab)	IL-23p19	100 mg每12周1次,皮下注射	200 mg每12周1次,皮下注射（病情急性加重或体重≥ 90 kg）
依奇珠单抗（ixekizumab）	IL-17A	80 mg每4周1次,皮下注射	80 mg每2周1次,皮下注射

英国《皮肤科医师协会银屑病生物制剂治疗指南》（2020版）解读

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 24

相关文章 12

编辑推荐

Metrics

本文评价

[1]	汤建平, 龚邦东. 干燥综合征的诊治现状、挑战和思考[J]. 诊断学理论与实践, 2022, 21(03): 291-298.
[2]	中国高血压联盟《动态血压监测指南》委员会. 2020中国动态血压监测指南[J]. 诊断学理论与实践, 2021, 20(01): 21-36.
[3]	黄丹, 陈崑. 银屑病相关流行病学调查进展[J]. 诊断学理论与实践, 2021, 20(01): 48-52.
[4]	戴生明. 银屑病关节炎的危害、诊治现状[J]. 诊断学理论与实践, 2018, 17(03): 238-243.
[5]	林镇, 郭茹茹, 吕良敬, 陈晓翔. Fra2通过调节白细胞介素23受体参与银屑病发病的研究[J]. 诊断学理论与实践, 2018, 17(03): 254-259.
[6]	刘亚群, 叶玲英, 吴歆, 徐沪济. 肿瘤坏死因子α拮抗剂在风湿免疫性疾病中的超适应证使用及其机制[J]. 诊断学理论与实践, 2016, 15(06): 632-636.
[7]	鲁智勇, 郑捷,. 银屑病病情严重程度的评价方法[J]. 诊断学理论与实践, 2009, 8(03): 360-362.
[8]	陈颖炜, 陈小英, 邬玉美, 鲁智勇, 薛峰, 潘萌, 施若非, 郑捷,. 银屑病患者白介素-20基因多态性和临床表型研究[J]. 诊断学理论与实践, 2008, 7(05): 521-525.
[9]	宋珺, 郑捷,. 银屑病与白细胞介素-10关系的研究进展[J]. 诊断学理论与实践, 2007, 6(01): 71-73.
[10]	陈珏, 曹华, 潘萌, 郑捷,. 寻常型银屑病伴大疱性皮肤病的诊断和临床分析[J]. 诊断学理论与实践, 2006, 5(04): 306-307.
[11]	时国朝,黄绍光. 无创正压通气应用的几个关键问题[J]. 诊断学理论与实践, 2005, 4(03): 248-250.
[12]	张华,吴达明,陈克敏. 介入放射学在急诊医学中的应用(1)[J]. 诊断学理论与实践, 2004, 3(02): 86-87.